PubMed Health⌕ Search

Biomedical subjects

G L Stimmel

Publications and source records attributed to G L Stimmel.

At least 19 recordsLinked to original sources
PubMed2000

Antipsychotic drug use patterns and the cost of treating schizophrenia.

This study investigated the relationships between antipsychotic drug use patterns and direct costs for 3,321 Medi-Cal patients with schizophrenia. Ordinary least-squares regression models were used to estimate the impact on costs of receiving antipsychotic drug treatment, delays in treatment, changes in therapy, and continuous therapy. Average costs were $25,940 per year per patient. Having used an antipsychotic drug was correlated with lower psychiatric hospital costs ($2,846 less) but higher nursing home costs. Completing one year of uninterrupted drug therapy was correlated with higher nursing home costs. Delayed drug treatment and changes in therapy increased the cost by $9,418 and $9,719, respectively.

Adult↗
PubMed1999

Management of and counseling for psychotropic drug-induced sexual dysfunction.

Clinicians are increasingly faced with the need to identify, treat, and counsel patients regarding psychotropic drug-induced sexual dysfunction. Antipsychotic and antidepressant drugs have both rational mechanisms to explain their effects on sexual function and established literature documenting these effects. The agents have potential for causing decreased libido, delayed ejaculation, and anorgasmia. Management and counseling can be highly effective for patients taking these agents.

Counseling↗
PubMed1999

Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

OBJECTIVE: We investigated the use patterns for antipsychotic medications generated by Medicaid patients with schizophrenia. METHOD: Paid claims data from the California Medicaid program (Medi-Cal) were used to identify 2655 patients with schizophrenia. Data from 1987-1996 were used, during which time Medi-Cal maintained prior authorization restrictions on second generation antipsychotic drugs. Prescription records were used to identify 3 patterns of antipsychotic drug use: no drug therapy for over 1 year; delayed onset of antipsychotic drug therapy; and switches in antipsychotic drugs within 1 year. Multiple logistic regression models were used to identify factors affecting these antipsychotic drug use patterns. RESULTS: Conventional antipsychotic medications account for over 98% of all patient treatment episodes. Over 24% of patients with schizophrenia do not use any antipsychotic medication for periods lasting up to 1 year. Over 24% of treated patients delayed the use of antipsychotic medications at least 30 days. For those patients who did not delay their use of antipsychotic medications, over 47% switched or augmented their initial antipsychotic medication during the first treatment year. Only 11.6% of treated patients achieved 1 year of uninterrupted antipsychotic drug therapy. The mean duration of uninterrupted therapy was 142 days. DISCUSSION: Antipsychotic drug use patterns suggest that conventional antipsychotic medications do not meet the therapeutic needs of patients with schizophrenia.

Ambulatory Care↗
PubMed1995

Factors predicting the use of multiple psychotropic medications.

BACKGROUND: Recent studies have questioned the appropriateness of some types of psychotropic medication prescribing, especially by general practitioners. The purpose of this study is to investigate factors that predict prescribing of multiple psychotropic medications, a class that may represent more complicated cases. METHOD: This study analyzed data from the 1989 National Ambulatory Medical Care Survey (NAMCS). Multiple logistic regression methods were used to determine variables that predicted the provision or ordering of multiple psychotropic medications during a single office visit. RESULTS: Patients who visited psychiatrists were six times more likely to receive psychotropics in combination than patients visiting general practitioners. Patients diagnosed as manic were four times more likely to receive multiple psychotropics, and those diagnosed as schizophrenic were three times more likely Patients visiting physicians in the Northeast and South were significantly less likely to receive psychotropics in combination than patients in the Midwest. CONCLUSION: Although general practice physicians contribute to the use of multiple psychotropic medications, patients visiting psychiatric specialists are much more likely to be provided combination therapy.

Adolescent↗
PubMed1992

Antidepressants and the risk of seizures.

As new antidepressants have been marketed, the issue of drug-induced seizures has assumed new relevance. The risk of such seizures depends on at least three critical factors. Of most importance are an individual's predisposing factors that may increase the risk, followed by the amount and rate of dosage titration, and the relative epileptogenic potential of the particular drug.

Antidepressive Agents↗
PubMed1990

The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.

Paid claims data from the California Medicaid (Medi-Cal) program were used to examine the utilization of antidepressants and to estimate the costs of antidepressant treatment failure for patients with major depressive disorders (MDD). Data for 6713 new patient episodes of antidepressant therapy were available for the analysis; over 45% of these patients never achieved a minimum daily dose of antidepressants indicative of treatment for depression and were excluded from further analysis. That left a possible depression patient population of 3664 patients of which 2344 patients had a minimum of 1 full year of post-episode data for analysis. Only 81 patients (3.5%) displayed antidepressant use patterns consistent with the successful treatment of MDD; 296 patients (12.6%) displayed use patterns suggestive of antidepressant treatment failure. The remaining 1967 (84%) patients could not be clearly classified; they were either (1) patients being treated for problems other than MDD, (2) MDD patients who were being prescribed subtherapeutic doses by their physician due to side effects or other reasons, (3) MDD patients who were noncompliant for a variety of reasons, or (4) MDD patients who had prematurely terminated antidepressant therapy. Multivariate regression analysis was used to estimate the costs associated with MDD treatment failure. These analyses indicated that MDD treatment failure resulted in increased costs of approximately $1043 in the first post-episode year (p less than .10). These increased costs were primarily due to higher hospital costs ($921, p less than .05), while drug costs were reduced by $222 (p less than .001).

Antidepressive Agents↗
PubMed1985

Accuracy and safety of a priori lithium loading.

A 30 mg/kg loading dose of slow-release lithium carbonate (Lithobid) was given in three divided doses to 38 patients to evaluate the accuracy and safety of achieving a therapeutic level in 12 hours. No patient experienced any adverse effects during the loading procedure or in the 12 hours after loading was completed. Prediction error (actual minus predicted level) for males was -0.11 mEq/L +/- 0.03 (SEM) with a mean absolute error of 0.16 mEq/L +/- 0.09 (SEM). Prediction error for females was -0.04 mEq/L +/- 0.07 (SEM) with a mean absolute error of 0.28 mEq/L +/- 0.14 (SEM). Lithium loading is safe and slightly overestimates the level actually achieved, except in obese females.

Adult↗
PubMed1983

A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients.

This article discusses a quasi-experimental study of the quality of pharmacists' and physicians' drug prescribing for ambulatory hypertensive patients in a health maintenance organization. The null hypothesis was that there is no difference between pharmacists and physicians as to the quality of drug prescribing for hypertensive patients. Analysis revealed no difference in prescribing between the physician group and the pharmacist group on the scoring for the presence of drug interactions, appropriateness of quantities, dose, and patient directions. The pharmacist prescriber group did significantly better than the physician group, however, on choosing the appropriate drug, prescribing for a "positive effect on the patient's health," and overall appropriateness from combining all the above scales (p less than 0.05). The diastolic pressures of the patients assigned to the pharmacists' group were not significantly different from the physicians' group on pretest, but on posttest the diastolic pressures were slightly lower in the pharmacists' group (p less than 0.10).

California↗
PubMed1983

Political and legal aspects of pharmacist prescribing.

The appropriateness of pharmacist prescribing is examined, and limits that should be incorporated into legislation are discussed. Arguments that support pharmacist prescribing are that (1) in current practice, pharmacist consultation has evolved into prescribing; (2) there is a need for pharmacists to prescribe; (3) nurse practitioners and physicians' assistants, whose training in clinical pharmacology is conducted by pharmacists, have authority to prescribe in many states; (4) as the need for dispensing functions decreases, new functions must be assumed; and (5) pharmacist prescribing in pilot studies has been safe, effective, and either equal or superior to physician prescribing. Negative aspects of pharmacist prescribing include (1) not all pharmacists are competent to prescribe, (2) pharmacists are not trained in diagnosis, (3) physicians oppose it, (4) it could increase patient-care costs, and (5) pharmacists' access to patient information is not adequate for competent prescribing. Based on these arguments, legislation regulating pharmacist prescribing should contain certain limits: (1) certification to prescribe should be based on demonstrated competence, (2) pharmacists who prescribe must have access to medical records, (3) pharmacists must prescribe within established working relationships with physicians, and (4) pharmacist prescribing should be limited to long-term therapy for chronic disease and therapy for acute self-limiting illnesses that are not diagnostically complex. These limitations have been incorporated into California law. A bill is pending that allows pharmacists, within specified guidelines, to initiate drug treatment.

California↗
PubMed1982

Pharmacists as drug prescribers: validation of certification exams and evaluation instruments.

The purpose of this article is to discuss the validity and reliability of certification tests and evaluation instruments for pharmacists as drug prescribers. Under California Law AB 717, the University of Southern California is operating one of two pilot programs to train and evaluate prescribing pharmacists. Various instruments have been created and administered, and validity results are presented. The presentation is organized into two areas dealing with the development of the examination instrument and then the assessment of the prescriptions written by pharmacists. The reliability of the three sections of the certification examination as measured by internal consistency was as follows: clinical therapeutics (KR 20=.84), physical assessment (KR 20=.88), and law (KR 20=.84). The exam was given to a group of physicians (N=14) to establish a cutting score. Thirty pharmacists who took the exam did slightly better than the physicians on clinical therapeutics, but the physicians performed better than pharmacists on physical assessment (p less than .01). A prescription evaluation form was constructed to evaluate the performance of the pharmacists as prescribers. The reliability of the form as measured by coefficient alpha was .84. Concurrent validity was explored by assessing the relationship between performance on the certification exam and judges' appropriateness scored on prescriptions for ambulatory hypertensive patients. These results indicate that the pharmacists, who passed the exam, can prescribe as appropriately as physicians.

California↗
PubMed1982

Comparison of pharmacist and physician prescribing for psychiatric inpatients.

Drug prescribing for inpatients by three certified pharmacist prescribers and two psychiatrists at a 40-bed mental health facility in California was evaluated. The pharmacist prescribers were assigned diagnosed patients whose treatment plan was primarily pharmacologic. For each prescriber, 60 prescriptions were randomly selected to include 20 neuroleptic drugs, 20 anticholinergic drugs used to alleviate the parkinsonism-like syndrome induced by neuroleptic drugs, and 20 antidepressants. A panel of four clinical judges independently evaluated the appropriateness of each prescription using explicit screening criteria; the judges' mean scores were reported. The patients treated by pharmacists and physicians were similar in age, sex ratio, number of drugs prescribed, and number of medical diagnoses. There was no significant difference in the appropriateness of prescribing between pharmacists and physicians for anticholinergic drugs, while mean scores for pharmacists were significantly better than physicians for neuroleptic and antidepressant drugs. The mean scores for all prescribers in most areas were in the appropriate range. While the results are not applicable to all pharmacists, the certified pharmacist prescribers in this study prescribed drugs for psychiatric inpatients as safely and appropriately as the physicians.

Antidepressive Agents↗
PubMed1981

The pharmacist as prescriber of drug therapy: the USC pilot project.

Recent legislation in California allows pilot projects to investigate prescribing by pharmacists. The University of Southern California School of Pharmacy project was approved in October, 1978. To be certified as prescribers, pharmacists must successfully complete a physical assessment course and a certifying examination. From an original group of 30 interested pharmacists, 25 were certified; five different pharmacists were added later. Prescribing pharmacists must meet with their supervising physician once every two weeks, and are restricted to the project formulary. A variety of health care settings are represented in the project, with pharmacists prescribing for ambulatory patients with chronic diseases, geriatric patients in extended care facilities, psychiatric patients, and selected inpatients. Project evaluation will continue through 1982 and will focus on safety and quality of care, patient acceptance, and cost of care.

California↗
PubMed1977

Clinical pharmacy services in mental health facilities.

The needs for clinical pharmacy services in mental health facilities have been identified, and a general, applicable role model description, which already is in practice across the country, has been given. Examples of implementation methods for institutions and for ambulatory care facilities have been described. Many pharmacists, particularly more recent graduates, already possess the skills necessary to provide clinical services in mental health facilities. These developments signal an end to the developmental phase of clinical mental health pharmacy practice and a beginning to the implementation phase of clinical mental health pharmacy practice.

Community Mental Health Services↗